To the question of differentiated therapy of urination disfunctions in multiple sclerosis patients

37 patients with multiple sclerosis who had complaints of urination disfunction have been investigated according to Poser criteria. On the basis of clinical and urometric studies (urofluometry) three main disfunctions of urinary bladder were determined. According to the type of urinary tract disfunctions a combination of medicinal preparations had been used. In a month patients of all the three groups had a significant improvement. In patients of the 1-st group urination frequency decreased by 35%, of the 2nd group by 34% and the quantity of residual urine reduced by 48%. In patients of the 3rd group quantity of residual urine came close to a norm, being decreased by 55%.

Download Full-text

Relationship between urodynamic findings and bowel function in multiple sclerosis patients with lower urinary tract dysfunction: Results from an Italian Cross-Sectional Study

10.26226/morressier.59b63e40d462b802923892e7 ◽

2017 ◽

Author(s):

Raffaele Balsamo

Keyword(s):

Multiple Sclerosis ◽

Urinary Tract ◽

Lower Urinary Tract ◽

Bowel Function ◽

Cross Sectional Study ◽

Lower Urinary Tract Dysfunction ◽

Sectional Study ◽

Cross Sectional ◽

Multiple Sclerosis Patients ◽

Lower Urinary

Download Full-text

5-year continuation rate of intra-vesical BoNTA injections in multiple sclerosis patients with lower urinary tract dysfunction: A retrospective study from the French Committee of Neuro-Urology

European Urology ◽

10.1016/s0302-2838(21)00416-4 ◽

2021 ◽

Vol 79 ◽

pp. S29

Author(s):

S. Delaval ◽

P.L. Dequirez ◽

X. Biardeau

Keyword(s):

Multiple Sclerosis ◽

Retrospective Study ◽

Urinary Tract ◽

Lower Urinary Tract ◽

Lower Urinary Tract Dysfunction ◽

Continuation Rate ◽

Multiple Sclerosis Patients ◽

Lower Urinary

Download Full-text

Treatment of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines

Canadian Urological Association Journal ◽

10.5489/cuaj.4059 ◽

2017 ◽

Vol 11 (3-4) ◽

pp. 110 ◽

Cited By ~ 10

Author(s):

Shachar Moshe Aharony ◽

Ornella Lam ◽

Jacques Corcos

Keyword(s):

Multiple Sclerosis ◽

Urinary Tract ◽

Lower Urinary Tract Symptoms ◽

Lower Urinary Tract ◽

Course Evaluation ◽

Disease Course ◽

Urinary Tract Symptoms ◽

Urological Complications ◽

Multiple Sclerosis Patients ◽

Lower Urinary

Multiple sclerosis (MS) is a unique neurological disease with a broad spectrum of clinical presentations that are time- and disease course-related. Lower urinary tract symptoms (LUTS) are highly prevalent in this patient population, with approximately 90% showing some degree of voiding dysfunction and/or incontinence 6–8 years after the initial MS diagnosis. Major therapeutic goals include quality of life improvement and the avoidance of urological complications Owing to the wide divergence of clinical symptoms and disease course, evaluation and treatment differ between patients. Treatment must be customized for each patient based on disease phase, patient independence, manual dexterity, social support, and other medical- or MS-related issues. Ablative or irreversible therapies are indicated only when the disease course is stable. In most cases of “safe” bladder, behavioural treatment is considered first-line defense. Antimuscarinic drugs, alone or in combination with intermittent self-catheterization, are currently the mainstay of conservative treatment, and several other medications may help in specific disease conditions. Second-line treatment includes botulinum toxin A injection, neuromodulation, indwelling catheters, and surgery in well-selected cases.

Download Full-text